Over the last few decades there have been numerous clinical trials utilizing central delivery of GDNF or neurturin via direct protein infusion or overexpression using viral vector-based gene therapy (Merola et al., 2010) with the latest trial reporting dosing of the first patient in September 2020. This opinion piece will summarize the discussion and the overarching recommendations from the meeting.
et al., 2019), leaving the field wondering if there is a future for these neurotrophic factors in PD (Kirkeby and Barker, 2019). Despite preclinical success, this trial, as all previously published trials, failed to demonstrate clinical efficacy (Whone A. et al., 2019) that utilized an enhanced method of protein infusion to facilitate improved spread of GDNF. The panel consisted of representatives from academia, industry, and non-profit organizations with primary backgrounds in neurology or neurosurgery and the impetus for the assembly was data from the a recent GDNF clinical trial (Whone A. Abstract: At the 2019 annual meeting for American Society of Neural Therapy and Repair (ASNTR) a special panel assembled to discuss the future of neurotrophic factor delivery in Parkinson's disease (PD), particularly those factors belonging to the Glial cell line-derived neurotrophic factor family of ligands (GFLs GDNF and Neurturin).
0 kommentar(er)
